Quick answer
What should a researcher know about tesamorelin in 2026? It is a full-length, 44-residue analog of GHRH with an N-terminal trans-3-hexenoyl cap that resists dipeptidyl peptidase-4. Published work falls into three layers (receptor pharmacology, animal studies, clinical trial reports) and each answers different questions. The V8 product is a 10 mg lyophilized vial listed at ≥98% HPLC purity, stored at 2–8 °C or −20 °C long-term. Use the calculator for volumes and read lot documents on the COA page. For laboratory research use only.
Tesamorelin is the most heavily modified full-length analog of growth-hormone-releasing hormone (GHRH) that laboratories can obtain, and that makes it a useful reference compound for anyone studying the GHRH receptor. This page is an orientation for 2026: what the molecule is, which questions the published literature has asked of it, how those papers are layered, and which bench readouts follow from each layer. It reports no news and makes no claim about any use outside the laboratory; it is meant to help a researcher decide whether, and how, the compound fits a study design.
What tesamorelin is, in one paragraph of chemistry
The tesamorelin product page describes a stabilized GHRH(1-44) analog: the complete 44-residue human GHRH sequence with a trans-3-hexenoyl group on the N-terminal tyrosine. The listed molecular formula is C221H366N72O67S, the sequence is given as trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg, and the material is a lyophilized powder in a 10 mg sealed clear glass vial with purity of ≥98% by HPLC. The hexenoyl cap is the only change from the native sequence. Native GHRH is cleaved after position 2 by dipeptidyl peptidase-4, and the cap is the reason the analog is more resistant to that cleavage in enzymatic-stability work.
For the full structural discussion, the library pillar tesamorelin research overview covers synthesis and mechanism, and what is tesa (tesamorelin) covers naming. This page deliberately starts one step later: given the molecule, how is the evidence organized?
A short timeline of the field
GHRH was first isolated and characterized in the early 1980s. Guillemin and colleagues purified a growth-hormone-releasing factor from a pancreatic tumor associated with acromegaly, and that work defined the sequence on which every later analog is built (Guillemin et al., 1982). The physiology that frames all later experiments, including the interplay of GHRH, somatostatin and ghrelin-pathway signaling in the pulsatile control of growth hormone, was consolidated in a comprehensive review of the neuroendocrine control of growth hormone secretion (Müller et al., 1999).
The practical problem for in-vivo and in-vitro work with native GHRH is its short life: enzymatic cleavage removes the first two residues and the remaining fragment is largely inactive at the receptor. Shorter truncated analogs, such as the 29-residue fragment, address length; the hexenoyl approach keeps the full 44 residues and protects the N-terminus. That is why tesamorelin sits alongside sermorelin and CJC-1295 in comparison designs, covered in tesamorelin vs sermorelin and tesamorelin vs CJC-1295.
Three layers of published evidence
The most common mistake when reading about a GHRH analog is to read every paper as the same kind of evidence. Sorting them first prevents that.
| Layer | What the papers do | What it can tell a bench scientist | What it cannot tell you |
|---|---|---|---|
| Receptor and cell pharmacology | Measure receptor binding, cAMP accumulation or growth-hormone release in pituitary cells or recombinant systems | Potency, efficacy and selectivity of the ligand in a defined system; a source of assay controls | How the ligand behaves in a whole organism with feedback loops |
| Animal studies | Follow growth-hormone and IGF-I axis readouts, tissue composition or metabolic markers in rodents and other species | Feedback behavior, kinetics and tissue-level endpoints under controlled husbandry | Direct transfer of any result to another species |
| Clinical trial reports | Report outcomes in human participants under regulated protocols | The most complete published picture of what the GHRH-axis analog does to IGF-I and body-composition endpoints in people | Anything about a research-grade material or a laboratory protocol; they are background, not instructions |
The best-known report in the third layer is the randomized, placebo-controlled trial by Falutz and colleagues in 412 adults with HIV and abdominal fat accumulation, with a primary end point of percent change in visceral adipose tissue measured by computed tomography over 26 weeks (Falutz et al., 2007). A second report (Falutz et al., 2010) examined the effects of the analog in people with HIV and excess abdominal fat. They are cited here to show how the field defines its end points, not to suggest that a laboratory material should be used in any similar way.
The GHRH axis a tesamorelin experiment has to respect
Growth hormone is released in pulses, and the pulses are shaped by two opposing hypothalamic signals: GHRH stimulates the somatotroph, somatostatin restrains it. A third input, ghrelin acting on the growth hormone secretagogue receptor, amplifies the response (Müller et al., 1999). A design that measures only a single time point after exposing cells or animals to a GHRH analog can therefore miss most of the biology. Three practical consequences follow.
- Sampling schedule. A pulsatile hormone needs several timed samples, not one. The question of "what changed" is often a question about pulse amplitude versus pulse frequency.
- Feedback. IGF-I feeds back on both the hypothalamus and the pituitary, so a long-running animal experiment measures a system that is adjusting itself. Acute cell assays remove that feedback, which is a strength for pharmacology and a weakness for physiology.
- Somatostatin tone. In primary pituitary cultures somatostatin is absent unless added, so responses can look larger than they would in the intact axis.
Bench readouts, matched to the question
| Question | Typical system | Readout | Control to include |
|---|---|---|---|
| Does the ligand activate the GHRH receptor? | Cells expressing the receptor, or primary pituitary cells | cAMP accumulation, growth-hormone release into medium | Native GHRH(1-44) at matched concentration; vehicle; an adenylyl-cyclase activator for the ceiling of the assay |
| Is it more stable than the native peptide? | Serum or purified dipeptidyl peptidase-4 incubations | LC-MS or HPLC time course of intact peptide | Native GHRH; a DPP-4 inhibitor control |
| How does it compare with shorter analogs? | Side-by-side concentration-response curves | EC50 and maximal response | Same cell passage, same day, same diluent |
| Does the vial match its label? | Receiving inspection | HPLC trace, mass, appearance | Lot certificate and a retained reference |
The stability row deserves emphasis. Because the compound's main design feature is protection of the N-terminus, an enzymatic-stability comparison is the cleanest experiment that tests whether the modification does what it was built to do. Run the incubation at physiologic temperature, quench aliquots at fixed times, and quantify the intact 44-residue species rather than total peptide, since fragments can co-elute in a short gradient.
Handling in brief
The product page gives the storage line as refrigerate at 2–8 °C, or −20 °C for long-term holding, protected from heat, moisture and light. A 44-residue peptide is larger than most single compounds in a research catalog, and larger peptides can take longer to dissolve fully. Let the vial warm to room temperature before opening so condensation does not wet the cake, run diluent down the glass wall instead of onto the powder, and swirl gently rather than shaking. Peptides in solution are exposed to deamidation, oxidation (methionine at position 27 is a candidate in this sequence) and aggregation, which is why solution time should be kept short and any freeze-thaw cycling limited (Manning et al., 2010).
The arithmetic is simple and does not change from compound to compound: concentration in mg/mL equals vial mass in mg divided by diluent volume in mL, and the molar concentration is that figure divided by the molar mass. Rather than tabulating figures here, use the reconstitution calculator and read tesamorelin reconstitution and storage for the step-by-step bench workflow. General background on the dry state is in what is lyophilization.
Quality checks before the first experiment
A single HPLC percentage is a statement about chromatographic purity, not about net peptide content. Counterions, residual water and related-substance peaks all matter for a molecule of this size. The checks a careful lab performs at receipt are the same ones described for the whole catalog: confirm the lot number against the document, read the HPLC trace and not just the headline number, confirm identity by mass where that capability exists, and record appearance. The product page states that batch-specific documents are published on the site where available; lot documents are collected on the COA page, and the interpretation of a tesamorelin trace is covered in tesamorelin purity testing. For the sourcing side of the question, see where to buy tesamorelin.
Where tesamorelin fits among GHRH-axis tools
| Tool | Receptor | Design feature | When a study design might pick it |
|---|---|---|---|
| Tesamorelin | GHRH receptor | Full-length 1-44 with N-terminal hexenoyl cap | Need a full-length, DPP-4-resistant GHRH ligand |
| Sermorelin | GHRH receptor | Truncated 1-29 fragment | Short-acting reference for receptor activation |
| CJC-1295 (no DAC) | GHRH receptor | Substituted 1-29 sequence for stability | Pulsatile-axis experiments with a stabilized fragment |
| Ipamorelin | Ghrelin (GHS) receptor | Pentapeptide secretagogue | Pairing an independent receptor pathway with GHRH signaling |
The comparison above is a map, not a recommendation. A study of receptor selectivity needs both GHRH and secretagogue ligands; a study of enzymatic stability needs the native peptide as the baseline. The pairing question is explored in tesamorelin and ipamorelin blend explained.
What is still open
Several questions are legitimately unsettled and are worth writing into a protocol as limitations rather than assumptions. How much of the in-vitro potency advantage over truncated analogs survives in serum-containing medium is assay-dependent. The behavior of the hexenoyl group during long storage in solution has not been described for research-grade material in the sources cited here. And the biological readouts most cited in the human literature, visceral fat by imaging and lipid panels, have no counterpart in a cell-culture experiment, so the translation between layers is something a design must argue for explicitly.
Frequently asked questions
What is tesamorelin in simple terms?
A synthetic analog of human growth-hormone-releasing hormone with all 44 amino acids and an N-terminal trans-3-hexenoyl group. It is used in the laboratory as a stabilized ligand for the GHRH receptor.
How is tesamorelin different from native GHRH?
The sequence is the same, but the hexenoyl cap on the N-terminal tyrosine makes the peptide more resistant to dipeptidyl peptidase-4, the enzyme that inactivates native GHRH by removing its first two residues.
What does the V8 tesamorelin vial contain?
The product page lists a 10 mg lyophilized powder in a sealed clear glass vial, purity of ≥98% by HPLC, and the molecular formula C221H366N72O67S. Lot documents are published on the COA page where available.
How should tesamorelin be stored?
The product page states refrigerate at 2–8 °C, −20 °C for long-term holding, and protect from heat, moisture and light.
Why is a single time point a weak design for a GHRH analog?
Growth hormone is released in pulses controlled by GHRH and somatostatin, so one sample can miss the effect. Timed series show amplitude and frequency changes that a single point hides.
What readouts suit a cell-based tesamorelin assay?
cAMP accumulation in receptor-expressing cells and growth-hormone release from primary pituitary cultures are the standard choices, each with native GHRH and vehicle controls.
How would a lab test whether the hexenoyl cap works?
Incubate tesamorelin and native GHRH with serum or purified dipeptidyl peptidase-4, take timed aliquots, and quantify the intact peptide by LC-MS or HPLC.
Does purity by HPLC equal peptide content?
No. HPLC percentage describes the share of the chromatogram that is the main peak. Water, counterions and related substances still occupy vial mass, so net peptide content is a separate measurement.
Is there a ready-made concentration table for tesamorelin?
This library gives the formula, concentration equals mass divided by volume, and points to the reconstitution calculator so every figure is computed from the actual vial and the chosen diluent volume.
Where can I read more about tesamorelin in the library?
Start with the tesamorelin research overview, then the purity-testing and reconstitution-and-storage articles linked above.
Research-use statement
Everything on this page is educational background for laboratory research use only. V8 Peptides products are sold as research materials, not for human or animal consumption, and nothing here describes a use outside the laboratory. Browse the research catalog, check lot documents on the COA page, or run volumes through the reconstitution calculator.
Related reading: Tesamorelin Clinical Literature: A Bench-Scientist Guide, Tesamorelin GHRH Receptor Mechanism: Assay Design, Tesamorelin Lab Applications: Readouts and Checks.
References
- Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218(4572):585-587. doi:10.1126/science.6812220
- Müller EE, Locatelli V, Cocchi D. Neuroendocrine control of growth hormone secretion. Physiol Rev. 1999;79(2):511-607. doi:10.1152/physrev.1999.79.2.511
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. doi:10.1056/NEJMoa072375
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat. J Clin Endocrinol Metab. 2010;95(9):4291-4304. doi:10.1210/jc.2010-0490
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
